The firm has achieved significant operational maturity, with net income rising from $7.0 million in 2024Q1 to $16.0 million in 2026Q1 alongside a disciplined 86.7% combined ratio.
| Revenue | 583.59M | 551.54M | 425.59M | 283.42M | 187.6M |
| Revenue Growth % | 27.5% | 29.59% | 50.16% | 51.07% | - |
| Medical Costs & Claims | 382.79M | 374.54M | 280.5M | 187.22M | 126.95M |
| Medical Cost Ratio % | 65.59% | 67.91% | 65.91% | 66.06% | 67.67% |
| Gross Profit | 200.8M | 177M | 145.1M | 96.2M | 60.65M |
| Gross Margin % | 34.41% | 32.09% | 34.09% | 33.94% | 32.33% |
| Gross Profit Growth % | - | 21.99% | 50.83% | 58.62% | - |
| Operating Expenses | 127.4M | 109.7M | 94.56M | 64.09M | 45.99M |
| OpEx / Revenue % | 21.83% | 19.89% | 22.22% | 22.61% | 24.51% |
| Depreciation & Amortization | 1.38M | 1.78M | 3.87M | 2.27M | 727K |
| Combined Ratio % | 87.42% | 87.8% | 88.13% | 88.67% | 92.19% |
| Operating Income | 73.4M | 67.3M | 50.53M | 32.12M | 14.66M |
| Operating Margin % | 12.58% | 12.2% | 11.87% | 11.33% | 7.81% |
| Operating Income Growth % | - | 33.17% | 57.36% | 119.05% | - |
| EBITDA | 74.78M | 69.08M | 54.4M | 34.38M | 15.39M |
| EBITDA Margin % | 12.81% | 12.52% | 12.78% | 12.13% | 8.2% |
| Interest Expense | 1.76M | 2.01M | 725K | 0 | 0 |
| Non-Operating Income | -1.76M | -2.01M | -725K | 0 | 0 |
| Pretax Income | 73.4M | 67.3M | 50.53M | 32.12M | 14.66M |
| Pretax Margin % | 12.58% | 12.2% | 11.87% | 11.33% | 7.81% |
| Income Tax | 15.03M | 13.51M | 12.29M | 7.07M | 3.4M |
| Effective Tax Rate % | 20.47% | 20.08% | 24.32% | 22.01% | 23.22% |
| Net Income | 58.37M | 53.79M | 38.24M | 25.05M | 11.26M |
| Net Margin % | 10% | 9.75% | 8.99% | 8.84% | 6% |
| Net Income Growth % | 36.84% | 40.64% | 52.69% | 122.52% | - |
| EPS (Diluted) | 1.75 | 1.59 | 1.29 | 0.79 | 0.36 |
| EPS Growth % | 32.06% | 23.26% | 63.29% | 119.44% | - |
| EPS (Basic) | - | 1.64 | 1.31 | 0.79 | 0.36 |
| Diluted Shares Outstanding | 33.28M | 33.65M | 29.68M | 31.53M | 31.53M |
Long-tail casualty reserve volatility
As reported in recent financial statements, Bowhead Specialty has maintained a robust growth trajectory, with quarterly revenue reaching $154.8 million in 2026Q1, representing a 26.1% year-over-year increase that underscores the firm's successful penetration into the competitive U.S. excess and surplus insurance market.
The consistent double-digit revenue growth suggests that Bowhead is effectively leveraging its specialized underwriting talent to capture market share in complex casualty lines. Investors should monitor whether this rapid expansion is achieved through disciplined rate increases or by loosening underwriting standards to chase volume in a hardening market.
Based on the company's reported figures, the combined ratio improved to 86.7% in 2026Q1, reflecting a significant recovery from the 93.0% level observed in 2023Q4 and indicating that the firm is successfully scaling its operations while maintaining a disciplined approach to underwriting profitability.
The compression of the combined ratio suggests that Bowhead is beginning to realize operating leverage as premium volume grows faster than fixed administrative costs. However, the volatility in the loss ratio, which spiked to 68.7% in 2025Q4, warrants further investigation into whether this reflects seasonal cat activity or underlying deterioration in casualty claims.
According to historical data, the period from 2024Q1 to 2026Q1 marks a critical inflection point where Bowhead transitioned from a startup-like cost structure to a more efficient operating model, evidenced by net income rising from $7.0 million to $16.0 million over the same timeframe.
This shift appears to validate the company's strategic partnership model, which provides the necessary financial backing to support rapid growth without the typical capital constraints of a new entrant. The sustainability of this earnings growth will likely depend on the company's ability to maintain underwriting discipline as its portfolio of policies matures.
While current profitability appears strong, the fact that Bowhead's loss reserves have not yet reached a steady state of maturity, as noted in recent filings, suggests that reported earnings may be sensitive to future adjustments in prior-year loss estimates as claims settle over time.
Investors should remain cautious regarding the potential for adverse reserve development, which is a common risk for specialty insurers in their early years of operation. If the company's initial loss picks prove overly optimistic, future earnings could face downward pressure regardless of current underwriting performance.
Quick answers to the most common questions about buying BOW stock.
For fiscal year 2025, Bowhead Specialty Holdings Inc. (BOW) reported total revenue of $551.5M. This represents a 194.0% increase compared to $187.6M in 2022.
Bowhead Specialty Holdings Inc. (BOW) is profitable, generating $53.8M in net income for the fiscal year ending 2025 with a net profit margin of 9.8%.
Bowhead Specialty Holdings Inc. (BOW) reported an operating income of $67.3M, resulting in an operating profit margin of 12.2%. This margin reflects the operational efficiency of the business before interest and taxes.
Bowhead Specialty Holdings Inc. (BOW) generated $177.0M in gross profit for the year, representing a gross profit margin of 32.1%. This demonstrates the company's core pricing power and production efficiency.